세계의 오가노이드 시장 : 제품 및 서비스별, 오가노이드 유형별, 용도별, 최종사용자별, 지역별 예측(-2032년)

Global Organoids Market Research Report Information By Product and Service (Product and Service), By Type of Organoids (Liver, Kidney, Pancreas, Intestine, Heart, and others), By Application (Drug Testing, Developmental Biology, Personalized Medicine, Regenerative Medicine, and Others), By End-Users (Academic and Research Institutes, Pharmaceutical and Biotechnology Company, Contract Research Organizations (CROs), and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) -Forecast Till 2032

Market Overview

In 2023, the Organoids Market was estimated to be worth USD 1.39 billion. The industry is anticipated to experience a compound annual growth rate (CAGR) of 23.55% from USD 1.68 billion in 2024 to USD 9.16 billion by 2032 during the forecast period (2024-2032). The market is experiencing growth due to the increasing demand for personalized medicine and the increasing application of drug discovery and toxicology studies.

The Organoids Market is being driven by the increasing demand for personalized medicine. Precision medicine, which is also referred to as personalized medicine, is characterized by the customization of medical treatment to the unique characteristics of each patient. This method is designed to deliver more effective and targeted therapies by taking into account factors such as genetic composition, environment, and lifestyle. Organoids are a critical instrument in the advancement of personalized medicine, as they are miniature 3D tissue structures that replicate the functionality and complexity of organs.

The acknowledgment of the significant variability in the way individuals respond to treatments is a critical component of personalized medicine. Animal models or 2D cell cultures are frequently employed in conventional drug development methods, but they do not accurately reflect human biology. Organoids provide a more physiologically relevant platform for the investigation of disease mechanisms and the assessment of drug responses. Researchers can gain a more comprehensive understanding of the distinctive characteristics of diseases and predict the responses of individuals to various treatments by utilizing patient-derived organoids.

Market segment insights

The Organoids Market has been segmented into product and service based on product and service.

The Organoids Market has been segmented into the following categories: Liver, Kidney, Pancreas, Intestine, Heart, and Others according to the variety of organoids.

The Market has been segmented into Drug Testing, Developmental Biology, Personalized Medicine, Regenerative Medicine, and Others, as determined by its application.

The Market has been segmented into Academic and Research Institutions, Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), and others based on End-Users.

Regional Perspectives

The Organoids Market has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World based on region. In 2023, North America held the largest market share, which is expected to increase to USD 3.42 billion by 2032, representing a compound annual growth rate (CAGR) of 22.88% during the forecast period.

Advancements in technology have facilitated the development of 3D organoids and spheroids, which have contributed to the rise in the use of organoid-based research models in the biotechnology sector of the United States and Canada. Major academic research institutions and biotechnology companies in the United States have been at the vanguard of the ongoing advancement of organoid technology.

Europe is the second-largest organoid market share, following the Americas region. Europe's substantial investment in life sciences and robust research infrastructure are significant factors. Renowned research institutions and biotechnology corporations that are at the forefront of organoid research are located in countries such as the United Kingdom, Germany, and the Netherlands.

The organoids market in the Asia Pacific region is experiencing substantial growth, which is being promoted by a variety of notable factors. Organoids, miniaturized organs that are three-dimensional and are derived from stem cells or tissue, have the potential to be used in regenerative medicine applications, drug discovery, and disease modeling.

Major Players

Merck KGgA, Corning Incorporated, STEMCELL Technologies, Bio-Techne, Molecular Devices, LLC, and Thermo Fisher Scientific Inc. are among the major participants in the Organoids Market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 Data Mining Process
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 Secondary Research data flow:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 Primary Research DATA FLOW:
  • 3.5.2 Primary Research: Number of Interviews conducted
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 Revenue Analysis Approach
• 3.7 DATA FORECASTING
  • 3.7.1 Data forecasting Type
• 3.8 DATA MODELING
  • 3.8.1 microeconomic factor analysis:
  • 3.8.2 Data modeling:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 DRIVERS
  • 4.2.1 Rising demand for personalized medicine
  • 4.2.2 Growing applications in drug discovery and toxicology studies
• 4.3 RESTRAINTS
  • 4.3.1 Regulatory challenges impacting market growth
  • 4.3.2 High cost of development and maintenance
• 4.4 OPPORTUNITY
  • 4.4.1 Technological advancements enhancing organoid production and applications
• 4.5 TREND
  • 4.5.1 Rising investment in regenerative medicine
  • 4.5.2 Expanding use in studying developmental biology
• 4.6 CHALLENGES
  • 4.6.1 Ethical concerns surrounding organoid sourcing and experimentation
  • 4.6.2 Integration challenges with existing medical practices and technologies
• 4.7 IMPACT ANALYSIS OF COVID-19
  • 4.7.1 Impact on R & D
  • 4.7.2 Impact on Supply Chain
  • 4.7.3 Impact on Pricing

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 Raw Material Sourcing and Research & Development (R&D)
  • 5.1.2 Organoid Production and Quality Control/Assurance
  • 5.1.3 Distribution and Logistics
  • 5.1.4 Application in Research, Drug Discovery, and Clinical Translation
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 Threat of New Entrants
  • 5.2.2 Bargaining Power of Suppliers
  • 5.2.3 Threat of Substitutes
  • 5.2.4 Bargaining Power of Buyers
  • 5.2.5 Intensity of Rivalry

6 GLOBAL ORGANOIDS MARKET, BY PRODUCT & SERVICE

• 6.1 OVERVIEW

7 GLOBAL ORGANOIDS MARKET, BY TYPE OF ORGANOIDS

• 7.1 OVERVIEW

8 GLOBAL ORGANOIDS MARKET, BY APPLICATION

• 8.1 OVERVIEW

9 GLOBAL ORGANOIDS MARKET, BY END-USERS

• 9.1 OVERVIEW

10 GLOBAL ORGANOIDS MARKET, BY REGION

• 10.1 GLOBAL
• 10.2 NORTH AMERICA
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 EUROPE
  • 10.3.1 germany
  • 10.3.2 France
  • 10.3.3 UK
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Rest of Europe
• 10.4 ASIA PACIFIC
  • 10.4.1 china
  • 10.4.2 India
  • 10.4.3 Japan
  • 10.4.4 South Korea
  • 10.4.5 Australia
  • 10.4.6 Rest of Asia Pacific
• 10.5 REST OF THE WORLD
  • 10.5.1 Middle East & Africa
  • 10.5.2 South America

11 COMPETITIVE LANDSCAPE

• 11.1 COMPETITIVE OVERVIEW
• 11.2 MAJOR PLAYERS IN THE GLOBAL ORGANOIDS MARKET
• 11.3 COMPETITIVE BENCHMARKING
• 11.4 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 11.4.1 Product launch/development
  • 11.4.2 Contract & Agreement

12 COMPANY PROFILES

• 12.1 HUB ORGANOIDS
  • 12.1.1 Company Overview
  • 12.1.2 FINANCIAL OVERVIEW
  • 12.1.3 Products/Services Offered
  • 12.1.4 KEY DEVELOPMENTS
  • 12.1.5 SWOT Analysis
  • 12.1.6 Key Strategies
• 12.2 NEYROBLASTGX
  • 12.2.1 COMPANY OVERVIEW
  • 12.2.2 FINANCIAL OVERVIEW
  • 12.2.3 PRODUCTS OFFERED
  • 12.2.4 KEY DEVELOPMENTS
  • 12.2.5 SWOT ANALYSIS
  • 12.2.6 KEY STRATEGIES
• 12.3 STEMCELL TECHNOLOGIES
  • 12.3.1 COMPANY OVERVIEW
  • 12.3.2 FINANCIAL OVERVIEW
  • 12.3.3 PRODUCTS OFFERED
  • 12.3.4 KEY DEVELOPMENTS
  • 12.3.5 SWOT ANALYSIS
  • 12.3.6 KEY STRATEGIES
• 12.4 BIO-TECHNE
  • 12.4.1 COMPANY OVERVIEW
  • 12.4.2 Financial Overview
  • 12.4.3 PRODUCTS OFFERED
  • 12.4.4 Key Developments
  • 12.4.5 SWOT ANALYSIS
  • 12.4.6 KEY STRATEGIES
• 12.5 THERMO FISHER SCIENTIFIC INC
  • 12.5.1 COMPANY OVERVIEW
  • 12.5.2 Financial Overview
  • 12.5.3 PRODUCTS OFFERED
  • 12.5.4 KEY DEVELOPMENTS
  • 12.5.5 SWOT ANALYSIS
  • 12.5.6 KEY STRATEGIES
• 12.6 3DNAMICS INC.
  • 12.6.1 COMPANY OVERVIEW
  • 12.6.2 FINANCIAL OVERVIEW
  • 12.6.3 PRODUCTS OFFERED
  • 12.6.4 KEY DEVELOPMENTS
  • 12.6.5 SWOT ANALYSIS
  • 12.6.6 KEY STRATEGIES
• 12.7 MOLECULAR DEVICES, LLC
  • 12.7.1 Company Overview
  • 12.7.2 FINANCIAL OVERVIEW
  • 12.7.3 Products/Services Offered
  • 12.7.4 Key Developments
  • 12.7.5 SWOT Analysis
  • 12.7.6 Key Strategies
• 12.8 MERCK KGGA
  • 12.8.1 COMPANY OVERVIEW
  • 12.8.2 Financial Overview
  • 12.8.3 PRODUCTS OFFERED
  • 12.8.4 KEY DEVELOPMENTS
  • 12.8.5 SWOT ANALYSIS
  • 12.8.6 KEY STRATEGIES
• 12.9 CORNING INCORPORATED
  • 12.9.1 COMPANY OVERVIEW
  • 12.9.2 Financial Overview
  • 12.9.3 PRODUCTS OFFERED
  • 12.9.4 KEY DEVELOPMENTS
  • 12.9.5 SWOT ANALYSIS
  • 12.9.6 KEY STRATEGIES
• 12.10 CN BIO INNOVATIONS LTD
  • 12.10.1 COMPANY OVERVIEW
  • 12.10.2 FINANCIAL OVERVIEW
  • 12.10.3 PRODUCTS OFFERED
  • 12.10.4 KEY DEVELOPMENTS
  • 12.10.5 SWOT ANALYSIS
  • 12.10.6 KEY STRATEGIES

13 DATA CITATIONS